Researchers have identified new drug targets for therapies that could benefit patients with different forms of retinitis pigmentosa and other inherited retinal diseases. Using advanced proteomics techniques, they unveiled shared critical pathways in retinitis pigmentosa disease models. The study represents significant progress in understanding how the proteome may change in different retinal dystrophies.